Bio: Ulka Vaishampayan, MD, is a Professor of Internal Medicine, Leader of the Translational and Clinical Research Program and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center. She serves as the Chair of the SWOG Advanced Renal Committee, is a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, and her research focuses on translational drug development. She is PI of the Dept of Defense Kidney Cancer Consortium site award and is a current recipient of the Prostate cancer Foundation Challenge Award. She is PI of the national phase III SWOG1931/PROBE trial. She is leading a “Women in RCC” initiative through KCA. She has completed leadership training and has acquired the prestigious Fellowship of the Advisory Board (FAB). Dr. Vaishampayan has >250 publications and is editor -in-chief of Journal of Kidney Cancer VHL (JKCVHL). She is a peer reviewer for multiple journals such as Lancet, Clin Cancer Res and J Clin Oncol and a grant reviewer for Dept of Defense, AACR, SITC and Kidney Cancer Association and KCCure. She has given multiple podium presentations at ASCO, ESMO and SITC. She has served as track leader for the Education committee for ASCO annual meeting, and as a Scientific review committee for ASCO. She has mentored trainees around the globe via ASCO mentorship program.